NASDAQ:KRYS Krystal Biotech (KRYS) Stock Price, News & Analysis $213.66 +2.97 (+1.41%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$211.01▼$219.3450-Day Range$156.35▼$213.6652-Week Range$93.95▼$219.34Volume234,535 shsAverage Volume380,332 shsMarket Capitalization$6.10 billionP/E Ratio114.26Dividend YieldN/APrice Target$177.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Krystal Biotech alerts: Email Address Krystal Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside16.9% Downside$177.63 Price TargetShort InterestBearish12.85% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment1.33Based on 6 Articles This WeekInsider TradingSelling Shares$7.68 M Sold Last QuarterProj. Earnings Growth101.40%From $2.15 to $4.33 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.19 out of 5 starsMedical Sector176th out of 936 stocksBiological Products, Except Diagnostic Industry19th out of 154 stocks 1.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKrystal Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Krystal Biotech's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.85% of the outstanding shares of Krystal Biotech have been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in Krystal Biotech has recently increased by 4.56%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 3.5 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 1.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Krystal Biotech this week, compared to 4 articles on an average week.MarketBeat Follows3 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,676,600.00 in company stock.Percentage Held by Insiders14.10% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Krystal Biotech's insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow by 101.40% in the coming year, from $2.15 to $4.33 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is 114.26, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is 114.26, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 148.37.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 7.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Krystal Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Krystal Biotech Stock (NASDAQ:KRYS)Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Read More KRYS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRYS Stock News HeadlinesJuly 26 at 8:00 AM | globenewswire.comKrystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024July 20, 2024 | americanbankingnews.comKrystal Biotech, Inc. Forecasted to Post Q2 2024 Earnings of $0.67 Per Share (NASDAQ:KRYS)July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.June 3, 2024 | insidermonkey.comIs Krystal Biotech, Inc. (NASDAQ:KRYS) the Premier Gene Therapy Stock for Your Portfolio?May 29, 2024 | msn.comStock Radar: LIC, Natco Pharma, Lumax Auto Tech, Adani Energy, Concord Biotech, Timken India in focus on TuesdayMay 15, 2024 | seekingalpha.comKrystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEBMay 15, 2024 | globenewswire.comKrystal Biotech to Present at the American Thoracic Society 2024 International ConferenceMay 8, 2024 | globenewswire.comKrystal Biotech to Present at BofA Securities 2024 Health Care ConferenceJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 7, 2024 | finance.yahoo.comKrystal Biotech, Inc. (NASDAQ:KRYS) Q1 2024 Earnings Call TranscriptMay 7, 2024 | markets.businessinsider.comMaintaining Buy Rating on Krystal Biotech: Strong VYJUVEK Sales and Promising Pipeline Despite EPS MissMay 7, 2024 | marketwatch.comKrystal Biotech Shares Drop After 1Q Earnings MissMay 7, 2024 | msn.comKrystal Biotech misses top-line and bottom-line estimates; reaffirms FY24 outlookMay 7, 2024 | finance.yahoo.comKrystal Biotech Inc (KRYS) (Q1 2024) Earnings Call Transcript Highlights: Robust Growth and ...May 7, 2024 | bizjournals.comKrystal Biotech adds to revenue despite challenges in Q1May 6, 2024 | markets.businessinsider.comKrystal Biotech Announces First Quarter 2024 Financial Results and Provides Business UpdatesMay 6, 2024 | finance.yahoo.comKrystal Biotech Inc (KRYS) Surpasses Revenue Estimates in Q1 2024May 6, 2024 | investorplace.comKRYS Stock Earnings: Krystal Biotech Beats EPS, Misses Revenue for Q1 2024See More Headlines Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Stock Price Target$177.63 High Stock Price Target$204.00 Low Stock Price Target$153.00 Potential Upside/Downside-16.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$1.87 Trailing P/E Ratio114.26 Forward P/E Ratio99.38 P/E GrowthN/ANet Income$10.93 million Net MarginsN/A Pretax Margin61.62% Return on Equity-5.74% Return on Assets-5.45% Debt Debt-to-Equity RatioN/A Current Ratio12.65 Quick Ratio12.42 Sales & Book Value Annual Sales$50.70 million Price / Sales120.36 Cash FlowN/A Price / Cash FlowN/A Book Value$27.60 per share Price / Book7.74Miscellaneous Outstanding Shares28,560,000Free Float24,531,000Market Cap$6.10 billion OptionableOptionable Beta0.84 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Krish S. Krishnan M.B.A. (Age 59)M.S., Founder, Chairman, President & CEO Comp: $1.07MMs. Suma M. Krishnan (Age 59)Founder, COO, President of R&D and Director Comp: $789.92kMs. Kathryn A. Romano (Age 42)Executive VP & Chief Accounting Officer Comp: $528.87kMr. John ThomasGeneral Counsel & Corporate SecretaryMr. John KarakkalVice President of North American Sales & MarketingMs. Christine WilsonHead of U.S. Sales and MarketingMr. Josh SuskinDirector of Human Resources & OperationsDr. Hubert C. Chen M.D. (Age 55)Senior Vice President of Clinical Development Mr. Laurent GouxSenior VP & GM of EuropeMr. Ram KamineniSenior Vice President of CMC & Technical OperationsMore ExecutivesKey CompetitorsBioCryst PharmaceuticalsNASDAQ:BCRXAlectorNASDAQ:ALECNantKwestNASDAQ:NKiTeos TherapeuticsNASDAQ:ITOSTaysha Gene TherapiesNASDAQ:TSHAView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 103,928 shares on 7/26/2024Ownership: 0.678%Allspring Global Investments Holdings LLCBought 18,021 shares on 7/26/2024Ownership: 0.618%EFG Asset Management North America Corp.Bought 60 shares on 7/26/2024Ownership: 0.044%Legato Capital Management LLCBought 2,222 shares on 7/26/2024Ownership: 0.008%Louisiana State Employees Retirement SystemBought 12,500 shares on 7/24/2024Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions KRYS Stock Analysis - Frequently Asked Questions How have KRYS shares performed this year? Krystal Biotech's stock was trading at $124.06 at the start of the year. Since then, KRYS stock has increased by 72.2% and is now trading at $213.66. View the best growth stocks for 2024 here. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) issued its earnings results on Monday, May, 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.17. Krystal Biotech's revenue was up 452400.0% on a year-over-year basis. When did Krystal Biotech IPO? Krystal Biotech (KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO. Who are Krystal Biotech's major shareholders? Krystal Biotech's top institutional shareholders include Bank of New York Mellon Corp (0.68%), Allspring Global Investments Holdings LLC (0.62%), Hennion & Walsh Asset Management Inc. (0.08%) and CWM LLC (0.05%). Insiders that own company stock include Krish S Krishnan, Suma Krishnan, Daniel Janney, Dino A Rossi, Kathryn Romano, Andrew C Orth and Julian S Gangolli. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv) and Verastem (VSTM). This page (NASDAQ:KRYS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Krystal Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
